Taysha Gene Therapies (NASDAQ:TSHA) Receives “Overweight” Rating from Cantor Fitzgerald

Taysha Gene Therapies (NASDAQ:TSHA)‘s stock had its “overweight” rating reiterated by research analysts at Cantor Fitzgerald in a report released on Tuesday, Benzinga reports. They presently have a $7.00 price objective on the stock. Cantor Fitzgerald’s target price suggests a potential upside of 189.26% from the company’s current price.

A number of other analysts have also recently weighed in on TSHA. JMP Securities reissued a “market outperform” rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a research report on Wednesday, March 20th. Canaccord Genuity Group reissued a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, March 21st. Needham & Company LLC reissued a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, April 11th. Piper Sandler initiated coverage on Taysha Gene Therapies in a research report on Tuesday, April 9th. They issued an “overweight” rating and a $9.00 price objective for the company. Finally, Chardan Capital raised their target price on Taysha Gene Therapies from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Thursday, March 21st. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $6.88.

Taysha Gene Therapies Stock Down 0.4 %

Shares of NASDAQ:TSHA opened at $2.42 on Tuesday. The company has a quick ratio of 4.08, a current ratio of 4.08 and a debt-to-equity ratio of 0.54. The stock has a market cap of $452.59 million, a P/E ratio of -3.61 and a beta of 0.29. The business’s 50 day moving average is $2.65 and its 200 day moving average is $2.09. Taysha Gene Therapies has a 52-week low of $0.50 and a 52-week high of $3.89.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its earnings results on Tuesday, March 19th. The company reported $0.35 earnings per share (EPS) for the quarter. The company had revenue of $3.60 million for the quarter, compared to the consensus estimate of $4.75 million. Sell-side analysts predict that Taysha Gene Therapies will post -0.39 EPS for the current year.

Hedge Funds Weigh In On Taysha Gene Therapies

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. FMR LLC raised its stake in shares of Taysha Gene Therapies by 2,035.0% during the 3rd quarter. FMR LLC now owns 24,527,801 shares of the company’s stock valued at $77,508,000 after buying an additional 23,378,974 shares during the last quarter. RA Capital Management L.P. purchased a new position in shares of Taysha Gene Therapies during the 3rd quarter valued at about $58,373,000. RTW Investments LP purchased a new position in shares of Taysha Gene Therapies during the 3rd quarter valued at about $53,382,000. Acuta Capital Partners LLC purchased a new position in shares of Taysha Gene Therapies during the 3rd quarter valued at about $12,096,000. Finally, Vanguard Group Inc. raised its stake in shares of Taysha Gene Therapies by 235.2% during the 3rd quarter. Vanguard Group Inc. now owns 5,327,864 shares of the company’s stock valued at $16,836,000 after buying an additional 3,738,616 shares during the last quarter. Hedge funds and other institutional investors own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.